<?xml version="1.0" encoding="UTF-8"?>
<p id="p0285">As mentioned before, IL-6 is an important component of the cytokine storm. So, the use of anti-IL-6 inhibitory agents, like Tocilizumab, Sarilumab, Siltuximab, which are all humanized mAbs, might reduce the adverse effects of CRS 
 <xref rid="b0085" ref-type="bibr">[17]</xref>. It must be noted that anti-GM-CSF mAbs like TJ003234, Gimsilumab, and Lenzilumab are also being evaluated against COVID-19. Moreover, inhibitors of the IL-1 family, IFN-γ cytokines, and the Janus kinase signal transducer and activator of transcription proteins (JAK-STAT) signaling pathway might also be useful for controlling the cytokine storm 
 <xref rid="b0600" ref-type="bibr">[120]</xref>.
</p>
